Drugs / MTX
last change Dec 2024 re-read 2 minutes ago

MTX

Developed for
central nervous system non-hodgkin lymphoma
Investigated by
Charite University, Berlin, Germany

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04841434 Jun 2021 → Dec 2024 central nervous system non-hodgkin lymphoma Charite University, Berlin, Germany Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MTX MTX is given at a dose according to the allocated dose level cohort as a 4-hour IV infusion.” NCT04841434